 Connection
Scott Berkowitz to Animals
This is a "connection" page, showing publications Scott Berkowitz has written about Animals.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.036 |
|
|
|
-
Goldenberg NA, Berkowitz SD, Betensky M, Holzhauer S, Ignjatovic V, Kiskaddon A, Schaufelberger D, Monagle P, Male C. Development of new antithrombotic drugs for children (part 1): guidance from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis and the Pedi-ATLAS Group. J Thromb Haemost. 2026 Sep; 24(9):3360-3368.
Score: 0.012
-
Berkowitz SD. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease. Haemostasis. 2000; 30 Suppl 3:27-43.
Score: 0.008
-
Sarich TC, Peters G, Berkowitz SD, Misselwitz F, Nessel CC, Burton P, Cook-Bruns N, Lensing AW, Haskell L, Perzborn E, Kubitza D, Moore KT, Jalota S, Weber J, Pan G, Sun X, Westermeier T, Nadel A, Oppenheimer L, DiBattiste PM. Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions. Ann N Y Acad Sci. 2013 Jul; 1291:42-55.
Score: 0.005
-
Zannad F, Stough WG, Regnault V, Gheorghiade M, Deliargyris E, Gibson CM, Agewall S, Berkowitz SD, Burton P, Calvo G, Goldstein S, Verheugt FW, Koglin J, O'Connor CM. Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. Int J Cardiol. 2013 Sep 01; 167(5):1772-82.
Score: 0.005
-
Misselwitz F, Berkowitz SD, Perzborn E. The discovery and development of rivaroxaban. Ann N Y Acad Sci. 2011 Mar; 1222:64-75.
Score: 0.004
-
Madan M, Berkowitz SD, Tcheng JE. Glycoprotein IIb/IIIa integrin blockade. Circulation. 1998 Dec 08; 98(23):2629-35.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|